دورية أكاديمية
Identification of mouse CD4 + T cell epitopes in SARS-CoV-2 BA.1 spike and nucleocapsid for use in peptide:MHCII tetramers.
| العنوان: | Identification of mouse CD4 + T cell epitopes in SARS-CoV-2 BA.1 spike and nucleocapsid for use in peptide:MHCII tetramers. |
|---|---|
| المؤلفون: | Bricio-Moreno L; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Barreto de Albuquerque J; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Neary JM; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States., Nguyen T; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States., Kuhn LF; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States., Yeung Y; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States., Hastie KM; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States., Landeras-Bueno S; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States., Olmedillas E; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States., Hariharan C; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States., Nathan A; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.; Program in Health Sciences and Technology, Harvard Medical School and Massachusetts Institute of Technology, Boston, MA, United States., Getz MA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States., Gayton AC; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States., Khatri A; Harvard Medical School, Boston, MA, United States.; Endocrine Division, MGH, Boston, MA, United States., Gaiha GD; Harvard Medical School, Boston, MA, United States.; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.; Division of Gastroenterology, MGH, Boston, MA, United States., Ollmann Saphire E; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States.; Department of Medicine, University of California San Diego, La Jolla, CA, United States., Luster AD; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Moon JJ; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Division of Pulmonary and Critical Care Medicine, MGH, Boston, MA, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Mar 11; Vol. 15, pp. 1329846. Date of Electronic Publication: 2024 Mar 11 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | COVID-19* , SARS-CoV-2*/chemistry, Animals ; Mice ; CD4-Positive T-Lymphocytes ; Epitopes, T-Lymphocyte ; Nucleocapsid/chemistry ; Peptides/chemistry ; Histocompatibility Antigens Class II/chemistry ; Spike Glycoprotein, Coronavirus/chemistry |
| مستخلص: | Understanding adaptive immunity against SARS-CoV-2 is a major requisite for the development of effective vaccines and treatments for COVID-19. CD4 + T cells play an integral role in this process primarily by generating antiviral cytokines and providing help to antibody-producing B cells. To empower detailed studies of SARS-CoV-2-specific CD4 + T cell responses in mouse models, we comprehensively mapped I-A b -restricted epitopes for the spike and nucleocapsid proteins of the BA.1 variant of concern via IFNγ ELISpot assay. This was followed by the generation of corresponding peptide:MHCII tetramer reagents to directly stain epitope-specific T cells. Using this rigorous validation strategy, we identified 6 immunogenic epitopes in spike and 3 in nucleocapsid, all of which are conserved in the ancestral Wuhan strain. We also validated a previously identified epitope from Wuhan that is absent in BA.1. These epitopes and tetramers will be invaluable tools for SARS-CoV-2 antigen-specific CD4 + T cell studies in mice. Competing Interests: GG receives research funding from Merck and Moderna. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Bricio-Moreno, Barreto de Albuquerque, Neary, Nguyen, Kuhn, Yeung, Hastie, Landeras-Bueno, Olmedillas, Hariharan, Nathan, Getz, Gayton, Khatri, Gaiha, Ollmann Saphire, Luster and Moon.) |
| التعليقات: | Update of: bioRxiv. 2023 Nov 17;:. (PMID: 38014059) |
| References: | J Immunol. 2021 Jun 1;206(11):2503-2507. (PMID: 33972373) Viruses. 2023 Mar 16;15(3):. (PMID: 36992472) Cell. 2020 Nov 12;183(4):1070-1085.e12. (PMID: 33031744) Nature. 2020 Oct;586(7830):509-515. (PMID: 32967005) Science. 2022 Nov 25;378(6622):eabo2523. (PMID: 36302057) Methods Mol Biol. 2018;1799:165-181. (PMID: 29956152) Sci Immunol. 2022 Jul 22;7(73):eabl9464. (PMID: 35857584) J Immunol. 2012 May 1;188(9):4135-40. (PMID: 22517866) Science. 2021 Oct 22;374(6566):472-478. (PMID: 34554826) Annu Rev Immunol. 2023 Apr 26;41:343-373. (PMID: 36750314) Vaccines (Basel). 2021 Jun 11;9(6):. (PMID: 34208032) Nature. 2021 Dec;600(7889):408-418. (PMID: 34880490) J Immunol Methods. 2006 May 30;312(1-2):12-9. (PMID: 16624319) Genome Med. 2021 Jun 14;13(1):101. (PMID: 34127050) Pathogens. 2023 Jun 22;12(7):. (PMID: 37513709) Nucleic Acids Res. 2019 Jul 2;47(W1):W502-W506. (PMID: 31114900) Annu Rev Pathol. 2024 Jan 24;19:69-97. (PMID: 37738512) Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127) Cell Rep Med. 2021 Jul 20;2(7):100355. (PMID: 34230917) J Immunol. 2009 Dec 15;183(12):7949-57. (PMID: 19923463) Cell. 2022 Mar 17;185(6):1041-1051.e6. (PMID: 35202566) J Vis Exp. 2012 Oct 22;(68):. (PMID: 23117190) PLoS Pathog. 2012 Jan;8(1):e1002499. (PMID: 22275869) Cell Rep. 2023 May 30;42(5):112421. (PMID: 37083327) J Immunol. 2021 Mar 1;206(5):931-935. (PMID: 33441437) Science. 2020 Sep 18;369(6510):1501-1505. (PMID: 32703906) J Exp Med. 2021 Apr 5;218(4):. (PMID: 33464307) J Virol. 2007 Jan;81(2):813-21. (PMID: 17079315) |
| معلومات مُعتمدة: | DP1 DA058476 United States DA NIDA NIH HHS; DP2 AI154421 United States AI NIAID NIH HHS; P01 AI165072 United States AI NIAID NIH HHS; R01 AI176533 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: C57BL/6; HexaPro; epitope mapping; immunodominance; vFLIP |
| المشرفين على المادة: | 0 (Epitopes, T-Lymphocyte) 0 (Peptides) 0 (Histocompatibility Antigens Class II) 0 (spike protein, SARS-CoV-2) 0 (Spike Glycoprotein, Coronavirus) |
| تواريخ الأحداث: | Date Created: 20240326 Date Completed: 20240327 Latest Revision: 20240408 |
| رمز التحديث: | 20240408 |
| مُعرف محوري في PubMed: | PMC10961420 |
| DOI: | 10.3389/fimmu.2024.1329846 |
| PMID: | 38529279 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1329846 |